The safety and optimal dosage of an interleukin-17A inhibitor (secukinumab) in the treatment of psoriatic arthritis in a patient with concomitant hepatitis C virus infection

The safety and optimal dosage of an interleukin-17A inhibitor (secukinumab) in the treatment of psoriatic arthritis in a patient with concomitant hepatitis C virus infection

Psoriatic arthritis (PsA) is a chronic inflammatory disease of the group of spondylitides, which is associated with psoriasis. The decisive role is played by the activation of the interleukin (IL)-23/IL-17 axis in the pathogenesis of PsA [1]. Secukinumab (SEC) is a fully human antibody that binds to...

Full description

Bibliographic Details
Main Authors: E. E. Gubar, T. V. Korotaeva, A. S. Starkova, M. M. Urumova
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2019-10-01
Series:Современная ревматология
Subjects:
псориатический артрит
хронический вирусный гепатит с
секукинумаб
Online Access:https://mrj.ima-press.net/mrj/article/view/962

Similar Items

Similar Items